Messenger RNA-based therapeutics for brain diseases: An animal study for augmenting clearance of beta-amyloid by intracerebral administration of neprilysin mRNA loaded in polyplex nanomicelles

Journal of Controlled Release

Volumn 235, Issue , 2016, Pages 268-275

  Lin, Chin Yu ^a   Perche, Federico ^a   Ikegami, Masaru ^a   Uchida, Satoshi ^a   Kataoka, Kazunori ^a,b   Itaka, Keiji ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Amyloid; Gene therapy; Messenger RNA; mRNA based therapeutics; Polyplex nanomicelle

Indexed keywords

ENCODING (SYMBOLS); GENE THERAPY; GENES; GLYCOPROTEINS; MAMMALS; METABOLISM; NEURODEGENERATIVE DISEASES; PROTEINS; RNA;

AMYLOID; AMYLOID PRECURSOR PROTEINS; DEGRADATION ACTIVITY; MESSENGER RNA; MRNA-BASED THERAPEUTICS; NANOMICELLE; THERAPEUTIC POTENTIALS; THERAPEUTIC STRATEGY;

NUCLEIC ACIDS;

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; MEMBRANE METALLOENDOPEPTIDASE; MESSENGER RNA; NANOCARRIER; NEPRILYSIN MESSENGER RNA; PLASMID DNA; POLYPLEX NANOMICELLE; UNCLASSIFIED DRUG; GREEN FLUORESCENT PROTEIN;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; FEMALE; GENE THERAPY; HISTOLOGY; IMMUNOCYTOCHEMISTRY; IN VITRO GENE TRANSFER; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; ANIMAL; BRAIN; BRAIN DISEASE; C57BL MOUSE; CELL CULTURE; CELL LINE; DISEASE MODEL; DRUG ADMINISTRATION ROUTE; GENETICS; HUMAN; METABOLISM; NERVE CELL; TUMOR CELL LINE;

AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; BRAIN DISEASES; CELL LINE; CELL LINE, TUMOR; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION ROUTES; FEMALE; GREEN FLUORESCENT PROTEINS; HUMANS; MICE, INBRED C57BL; NEPRILYSIN; NEURONS; RNA, MESSENGER;

EID: 84973861994     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2016.06.001     Document Type: Article

References (24)

1. R. Jones Neurological disorders: two sides to beta-amyloid Nature reviews. Neuroscience 13 2012 666
2. J. Hardy, and D.J. Selkoe The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics Science 297 2002 353 356
3. R.E. Tanzi, and L. Bertram Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective Cell 120 2005 545 555
4. I. Klyubin, D.M. Walsh, C.A. Lemere, W.K. Cullen, G.M. Shankar, V. Betts, E.T. Spooner, L. Jiang, R. Anwyl, D.J. Selkoe, and M.J. Rowan Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo Nat. Med. 11 2005 556 561
5. S.M. Huang, A. Mouri, H. Kokubo, R. Nakajima, T. Suemoto, M. Higuchi, M. Staufenbiel, Y. Noda, H. Yamaguchi, T. Nabeshima, T.C. Saido, and N. Iwata Neprilysin-sensitive synapse-associated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function J. Biol. Chem. 281 2006 17941 17951
6. H.J. Huang, K.C. Liang, C.P. Chen, C.M. Chen, and H.M. Hsieh-Li Intrahippocampal administration of A beta(1-40) impairs spatial learning and memory in hyperglycemic mice Neurobiol. Learn. Mem. 87 2007 483 494
7. S. Nakamura, N. Murayama, T. Noshita, H. Annoura, and T. Ohno Progressive brain dysfunction following intracerebroventricular infusion of beta(1-42)-amyloid peptide Brain Res. 912 2001 128 136
8. N. Iwata, S. Tsubuki, Y. Takaki, K. Shirotani, B. Lu, N.P. Gerard, C. Gerard, E. Hama, H.J. Lee, and T.C. Saido Metabolic regulation of brain Abeta by neprilysin Science 292 2001 1550 1552
9. N. Iwata, M. Sekiguchi, Y. Hattori, A. Takahashi, M. Asai, B. Ji, M. Higuchi, M. Staufenbiel, S. Muramatsu, and T.C. Saido Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice Sci. Rep 3 2013 1472
10. S.S. El-Amouri, H. Zhu, J. Yu, R. Marr, I.M. Verma, and M.S. Kindy Neprilysin: an enzyme candidate to slow the progression of Alzheimer's disease Am. J. Pathol. 172 2008 1342 1354
11. T. Bettinger, R.C. Carlisle, M.L. Read, M. Ogris, and L.W. Seymour Peptide-mediated RNA delivery: a novel approach for enhanced transfection of primary and post-mitotic cells Nucleic Acids Res. 29 2001 3882 3891
12. S. Zou, K. Scarfo, M.H. Nantz, and J.G. Hecker Lipid-mediated delivery of RNA is more efficient than delivery of DNA in non-dividing cells Int. J. Pharm. 389 2010 232 243
13. N. Kanayama, S. Fukushima, N. Nishiyama, K. Itaka, W.D. Jang, K. Miyata, Y. Yamasaki, U.I. Chung, and K. Kataoka A PEG-based biocompatible block catiomer with high buffering capacity for the construction of polyplex micelles showing efficient gene transfer toward primary cells ChemMedChem 1 2006 439 444
14. K. Miyata, N. Nishiyama, and K. Kataoka Rational design of smart supramolecular assemblies for gene delivery: chemical challenges in the creation of artificial viruses Chem. Soc. Rev. 41 2012 2562 2574
15. K. Itaka, T. Ishii, Y. Hasegawa, and K. Kataoka Biodegradable polyamino acid-based polycations as safe and effective gene carrier minimizing cumulative toxicity Biomaterials 31 2010 3707 3714
16. S. Uchida, K. Itaka, H. Uchida, K. Hayakawa, T. Ogata, T. Ishii, S. Fukushima, K. Osada, and K. Kataoka In vivo messenger RNA introduction into the central nervous system using polyplex nanomicelle PLoS One 8 2013 e56220
17. M. Baba, K. Itaka, K. Kondo, T. Yamasoba, and K. Kataoka Treatment of neurological disorders by introducing mRNA in vivo using polyplex nanomicelles J. Control. Release 201 2015 41 48
18. S. Holtkamp, S. Kreiter, A. Selmi, P. Simon, M. Koslowski, C. Huber, O. Tureci, and U. Sahin Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells Blood 108 2006 4009 4017
19. K.B.J. Franklin, and G. Paxinos Paxinos and Franklin's The Mouse Brain in Stereotaxic Coordinates Fourth edition 2012 Academic press
20. A. Fasbender, J. Zabner, B.G. Zeiher, and M.J. Welsh A low rate of cell proliferation and reduced DNA uptake limit cationic lipid-mediated gene transfer to primary cultures of ciliated human airway epithelia Gene Ther. 4 1997 1173 1180
21. I. Roy, and N. Vij Nanodelivery in airway diseases: challenges and therapeutic applications Nanomedicine: nanotechnology, biology, and medicine 6 2010 237 244
22. A. Subramanian, P. Ranganathan, and S.L. Diamond Nuclear targeting peptide scaffolds for lipofection of nondividing mammalian cells Nat. Biotechnol. 17 1999 873 877
23. A. Matsui, S. Uchida, T. Ishii, K. Itaka, and K. Kataoka Messenger RNA-based therapeutics for the treatment of apoptosis-associated diseases Sci Rep 5 2015 15810
24. K. Shirotani, S. Tsubuki, N. Iwata, Y. Takaki, W. Harigaya, K. Maruyama, S. Kiryu-Seo, H. Kiyama, H. Iwata, T. Tomita, T. Iwatsubo, and T.C. Saido Neprilysin degrades both amyloid beta peptides 1-40 and 1-42 most rapidly and efficiently among thiorphan- and phosphoramidon-sensitive endopeptidases J. Biol. Chem. 276 2001 21895 21901